InnoCare Pharma Limited (9969.HK)

HKD 6.1

(0.16%)

Operating Income Summary of InnoCare Pharma Limited

InnoCare Pharma Limited's latest annual operating income in 2023 was -651.15 Million CNY , up 20.58% from previous year.
InnoCare Pharma Limited's latest quarterly operating income in 2024 Q1 was -161.85 Million CNY , up 16.13% from previous quarter.
InnoCare Pharma Limited reported an annual operating income of -891.62 Million CNY in 2022, down -3576.8% from previous year.
InnoCare Pharma Limited reported an annual operating income of -24.25 Million CNY in 2021, up 94.78% from previous year.
InnoCare Pharma Limited reported a quarterly operating income of -133.18 Million CNY for 2024 Q2, up 24.49% from previous quarter.
InnoCare Pharma Limited reported a quarterly operating income of -708.13 Million CNY for 2023 FY, up 20.58% from previous quarter.

Annual Operating Income Chart of InnoCare Pharma Limited (2023 - 2017)

Historical Annual Operating Income of InnoCare Pharma Limited (2023 - 2017)

Year	Operating Income	Operating Income Growth
2023	-651.15 Million CNY	20.58%
2022	-891.62 Million CNY	-3576.8%
2021	-24.25 Million CNY	94.78%
2020	-464.89 Million CNY	78.41%
2019	-2.15 Billion CNY	-1348.52%
2018	-148.64 Million CNY	-121.79%
2017	-67.02 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-161.85 Million CNY	16.13%
2024 Q2	-133.18 Million CNY	24.49%
2023 FY	-708.13 Million CNY	20.58%
2023 Q4	-192.98 Million CNY	-207.25%
2023 Q3	-62.8 Million CNY	71.28%
2023 Q1	-14.22 Million CNY	96.19%
2023 Q2	-218.69 Million CNY	-1436.86%
2022 Q4	-373.51 Million CNY	-500.93%
2022 Q3	-62.15 Million CNY	64.89%
2022 Q2	-177.03 Million CNY	-18.71%
2022 Q1	-149.12 Million CNY	43.48%
2022 FY	-891.62 Million CNY	-3576.8%
2021 Q1	-138.39 Million CNY	-1.22%
2021 Q3	358.08 Million CNY	358.74%
2021 Q4	-263.82 Million CNY	-173.68%
2021 Q2	-138.39 Million CNY	0.0%
2021 FY	-24.25 Million CNY	94.78%
2020 FY	-464.89 Million CNY	78.41%
2020 Q1	-142.76 Million CNY	90.47%
2020 Q3	-136.73 Million CNY	4.22%
2020 Q2	-142.76 Million CNY	0.0%
2020 Q4	-136.73 Million CNY	0.0%
2019 Q3	-327.02 Million CNY	-489.28%
2019 Q2	-55.49 Million CNY	0.0%
2019 Q1	-55.49 Million CNY	40.36%
2019 FY	-2.15 Billion CNY	-1348.52%
2019 Q4	-1.49 Billion CNY	-357.92%
2018 Q3	-47.34 Million CNY	-37.95%
2018 Q4	-93.05 Million CNY	-96.53%
2018 Q1	-34.32 Million CNY	0.0%
2018 Q2	-34.32 Million CNY	0.0%
2018 FY	-148.64 Million CNY	-121.79%
2017 FY	-67.02 Million CNY	0.0%

Peer Operating Income Comparison of InnoCare Pharma Limited

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	1060.858%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	172.515%